Home Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play
 

Keywords :   


Portola Reports Q4, Updates Business Plans: Analysis Of This High-Risk Play

2016-03-02 23:40:43| Biotech - Topix.net

I first bought and wrote about Portola Pharmaceuticals in mid-2014, when the stock was revisiting its brief peak around $30 that it first hit in September 2013. It had IPO'ed in May at $15, so Friday's closing price of $27.79 still represents a successful IPO.

Tags: business play reports analysis

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Weekly Recap: U.S. House Approves WIPPES Legislation, Drylock Holds Private Label Academy & More
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
16.06Atlantic Tropical Weather Outlook
16.06Eastern North Pacific Tropical Weather Outlook
15.06Atlantic Tropical Weather Outlook
More »